Presentationer och intervjuer

  Presentation Media Date

AlzeCure medverkar på Erik Penser Banks temadag Life Science den 2 december, 2021

2 december, 2021

Follow us – Stay updated

22 november, 2021

AlzeCure Pharma – Redeye Life Science Day

11 november, 2021

AlzeCure update on the latest developments – Interview with CEO Martin Jönsson about the company, its projects developments in Alzheimer’s and pain, and future plans.

22 oktober, 2021

Alzecure presents at Healthcare Innovation Summit

7 oktober, 2021

Alzecure Pharma – Naventus Life Science Summit

29 september, 2021

Aktiespararna intervjuar VD Martin Jönsson – senaste kvartalsrapporten och framtidsutsikterna

20 september, 2021

AlzeCure Pharma – Aktiedagen Stockholm

7 september, 2021

Development plan for NeuroRestore ACD856 by Dr Johan Sandin, PhD Chief Scientific Officer

1 september, 2021

NeuroRestore Background and evolution by Dr Pontus Forsell, PhD Head of Discovery & Research

1 september, 2021

Company Overview & Vision by Martin Jönsson CEO

1 september, 2021

Alzheimer’s disease and the neurotrophins BDNF/NGF by Prof. Maria Eriksdotter M.D., PhD

1 september, 2021

Strategy Update on Alzheimer’s Disease & NeuroRestore

1 september, 2021

ACD856 – a novel positive allosteric modulator of Trk-receptors in clinical development for the treatment of Alzheimer’s disease; Scientific presentation at AAIC, July 26-30, 2021

29 juli, 2021

Om AlzeCures uppkomst och utveckling – Ett embryo som kan bli något stort – med Bengt Winblad, professor, senior vid Karolinska Institutet.

11 juni, 2021

Om Alzstatin och läkemedel vid Alzheimers sjukdom – med Bengt Winblad, professor, senior vid Karolinska Institutet.

11 juni, 2021

Om att drabbas av Alzheimers sjukdom, diagnostik, vården idag samt framtida behov – med Bengt Winblad, professor, senior vid Karolinska Institutet.

11 juni, 2021

Negativa allosteriska modulatorer av TrkA för behandling av smärta – Vetenskaplig presentation på smärtkonferensen IASP, juni 2021

11 juni, 2021

ACD440 – A Novel TRPV1 Antagonist for the Topical Treatment in Neuropathic Pain – Vetenskaplig presentation på smärtkonferensen IASP, juni 2021

9 juni, 2021

Alzecure: VD Martin Jönsson presenterar på Redeye Growth Day

7 juni, 2021

CEO Martin Jönsson after the company’s annual meeting

17 maj, 2021

Update on Progress in the Painless Platform, May 11, 2021

11 maj 2021

Chronic Pain – a high unmet medical need by CMO Märta Segerdahl, 11 Maj, 2021

11 maj, 2021

Company overview and goals by CEO Martin Jönsson, 11 Maj, 2021

11 maj, 2021

ACD 440 – A novel VR1 antagonist for neuropathic pain by CSO Johan Sandin, 11 Maj, 2021

11 maj, 2021

TrkA- NAM – Project in osteoarthritis & other severe pain conditions by Head of Discovery & Research Pontus Forsell, 11 Maj, 2021

11 maj, 2021

Alzecure: Interview with CEO Martin Jönsson and CSO Johan Sandin (video)

20 april 2021

Analysguiden: ”Smärtprojekt, en dold diamant”

10 mars 2021

Alzecure: Intervju med vd Martin Jönsson (video)

1 mars 2021

Analysguiden: Intervju med AlzeCure Pharma ”Vi har tagit stora kliv under 2020”

8 februari 2021

VD Martin Jönsson presentation, Aktiedagen Lund

27 januari 2021

Intervju med Johan Sandin (CSO) i Aktiespararnas analysguide

22 januari 2021

Improving Quality of Life for People with Neurodegenerative Diseases – Stockholm Researchers and Health Tech Companies

14 januari 2021